Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer
- 297 Downloads
In recent years, new therapeutic options have brought improvements in the treatment of metastatic, castration-resistant prostate cancer. Targeted Hormone Therapy (THT) represents a novel therapeutic component for which recent studies have shown a maximum benefit in the time between failure of androgen deprivation therapy (patient is metastatic and still pain-free) and prior to chemotherapy. Prostate cancer experts of the Austrian Society of Urology and Andrology (ÖGU), the Working Group for Urologic Oncology as part of the ÖGU, and the Professional Association of Austrian Urologists (BvU) have developed recommendations for the treatment of patients with asymptomatic or mildly symptomatic metastatic, castration-resistant prostate cancer. The definition of failure of classical hormonal therapy has been based on the guidelines of the German Society of Urology (Deutsche Gesellschaft für Urologie, DGU) and the European Association of Urology (EAU). Criteria for the initiation of treatment with hormonal or chemotherapy include:
Castration resistance with increase of prostate-specific antigen (PSA)
Evidence of metastases in imaging
No or mild symptoms
Quality of Life Index of the Eastern Cooperative Oncology Group (ECOG) 0-1 (ECOG 2 requires individualized decision) .
Treatment should only be initiated when all of these four criteria are applicable, with the age of the patient being no exclusion criterion. First-line therapies for these patients include abiraterone, enzalutamide, and docetaxel as well as radium-223. The manuscript refers only to treatment regimens available in Austria.
Selection of the initial treatment option—starting with THT or chemotherapy—should be determined based on the individual patient characteristics. When using abiraterone or enzalutamide, re-staging within 3–6 months is recommended.
KeywordsMetastatic, castration-resistant prostate cancer Treatment sequence Targeted Hormone Therapy Abiraterone Enzalutamide
Androgen deprivation therapy
Androgen receptor splice variant-7
American Urological Association
Working Group of Urologic Oncology (Arbeitskreis für Urologische Onkologie)
Professional Association of Austrian Urologists (Berufsverband der Österreichischen Urologen)
Castration-resistant prostate cancer
German Society of Urology (Deutsche Gesellschaft für Urologie)
European Association of Urology
Quality of Life Index of the Eastern Cooperative Oncology Group
European Society for Medical Oncology
- Hb drop
Metastatic, castration-resistant prostate cancer
Magnetic resonance imaging
Austrian Society of Urology and Andrology (Österreichische Gesellschaft für Urologie und Andrologie)
Positron emission tomography
Response Evaluation Criteria in Solid Tumors
Radiographic progression-free survival
Targeted Hormone Therapy
Compliance with ethical standards
Conflict of interests
The technical organization and conduct of the consensus meeting and the subsequent coordination process as well as the publication of the consensus statements have been facilitated by the company Janssen, though without any influence on the content. The authors declare that there has been no conflict of interests with regard to the publication of this article.
- 1.Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16(2):152–60. doi: 10.1016/S1470-2045(14)71205-7.CrossRefPubMedGoogle Scholar
- 6.Heidenreich A, et al. European Association of Urology Guidelines on Prostate cancer 2009, www.uroweb.org/guidelines/online-guidelines.
- 11.Horwich A, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;00:1–22.Google Scholar
- 14.Tombal B, et al. Enzalutamide in Men with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated Overall Survival Analysis of the Phase 3 PREVAIL Study. EAU 20.-24.3.2015 Madrid, Oral Presentation.Google Scholar
- 16.M Stein. ASCO Annual Meeting. 2014. (30.5–3.6.2014), Oral Presentation.Google Scholar
- 18.Parker C, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol. 2012;30(5):abstract LBA 4512.Google Scholar
- 19.Mottet N, et al. European Association of Urology Guidelines on Prostate cancer, www.uroweb.org/guidelines/online-guidelines.
- 20.National Cancer Institute (14.06.2010). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QiuckReference_5×7.pdf (abgerufen am 15.07.2014).
- 21.S3-Leitlinie Prostatakarzinom ILeitliniederQS3zurF. Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Version 3.0, September 2014, AWMF-Register-Nummer 043/022OL.Google Scholar